Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.53 |
| ▸ | PDE5A | O76074 | 3/20 | 0.51 |
| ▸ | CCR1 | P32246 | 3/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815997 | 0.88 | PDE4B (0.67) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4814793 | 0.86 | NR3C1 (0.58) | NR3C1PDE4BPDE5APGR | |
| SCHEMBL4815719 | 0.85 | NR3C1 (0.55) | NR3C1PDE4BPDE5ACCR1PGR | |
| SCHEMBL4808833 | 0.85 | NR3C1 (0.55) | NR3C1PDE4BPDE5ACCR1PGR | |
| SCHEMBL4341591 | 0.83 | PDE4B (0.67) | NR3C1PDE4B | |
| SCHEMBL4340409 | 0.82 | PDE4B (0.80) | NR3C1PDE4B | |
| SCHEMBL4337528 | 0.82 | PDE4B (0.65) | NR3C1PDE4B | |
| SCHEMBL4335219 | 0.81 | PDE4B (0.63) | NR3C1PDE4B | |
| SCHEMBL4930641 | 0.81 | PDE4B (0.63) | NR3C1PDE4BPDE5A | |
| SCHEMBL4937171 | 0.80 | PDE4B (0.62) | NR3C1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465743-B2 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-12-16 | — | — | US | claimed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | claimed |
| US-7465743-B2 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| EP-1735315-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005090353-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167485-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors | PDE3B, PDE3A, PDE4A | NR3C1 359/4885PDE4B 4/4885PDE5A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.